Emerging Companies

The study provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy.

The health reform debate is heating up and, in at least one respect, slowing down a bit.

Tracy Krughoff speaks with Fernando Quesada, executive director of the Biotechnology Center of Excellence Corporation, who is organizing Mexico’s participation in the BIO International Convention.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

States and regions throughout the United States are investing to create a business climate that supports the specific needs of the biosciences sector.

Dr. Moira Gunn and David Ewing Duncan report from the BIO International Convention.

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

April 29 2016
Bill would enhance the voice of emerging companies at the SEC Washington, D.C. (April 29, 2016) – Today, the Biotechnology Innovation Organization (BIO) applauds Senators Heidi Heitkamp (D-ND), Dean Heller (R-NV) and Gary Peters (D-MI) for introducing the SEC Small Business Advocate Act, which would ensure that growing companies have a strong, independent voice at the Securities and Exchange Commission (SEC). 
February 9 2016
Elements of the President’s budget proposal for 2017 directly threaten his Administration’s goal of curing cancer through advances in precision medicine
February 2 2016
BIO applauds the House of Representatives for approving the SEC Small Business Advocate Act (H.R. 3784) and the Small Business Capital Formation Enhancement Act (H.R. 4168). These bills would enhance the role that small businesses play in the decision-making process at the Securities and Exchange Commission, ensuring that SEC policies support the growth of emerging biotech innovators.
December 16 2015
BIO today welcomed legislation to extend critical tax incentives that are important to biotechnology companies. The legislation would make permanent the important Research & Development Tax Credit.
December 2 2015
BIO supports legislation to follow up on the success of the JOBS Act